Latest revenue
$37.2M
as of 2026-03-31
Latest net income
$-53.2M
as of 2026-03-31
Net margin
-142.8%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $342.3M
- Enterprise value
- $342.3M
- P/E (trailing)
- 9.2×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $7.08
- 52-wk low
- $2.04
- Beta
- —
- Shares out
- 128.7M
5-year trend
What this company does
ITEM 1. BUSINESS Overview Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets. Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have Premarket Application (“PMA”) approval, or 510(k) clearance from the United States Food and Drug Administration (“FDA”). Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease. We offer our…
AI summary unavailable — showing raw filing excerpt
Generated from ORGO's filing dated 2026-02-26
Key risks
Item 1A. Risk factors An investment in our securities, including our common stock, involves a high degree of risk. Investors should carefully consider the risks and uncertainties described below, together with the information included elsewhere in this Annual Report on Form 10-K and other documents we file with the SEC. Risks Related to Organogenesis and its business Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control. We are subject to the following factors, among others, that may negatively affect our operating results: •the announcement or introduction of new products by our competitors; •failure of government…
AI summary unavailable — showing raw filing excerpt
Generated from ORGO's filing dated 2026-02-26
Profitability
Gross margin
76.0%
0.8%Operating margin
7.9%
3076.5%Net margin
6.6%
779.9%Return on equity
12.3%
802.1%Return on assets
6.2%
756.4%Leverage
Debt / equity
0.99×
11.3%Long-term debt / equity
0.04×
1460.1%Debt / assets
49.9%
5.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $37.2M | -57.1% | $-53.2M | -182.1% | -142.8% |
Q4 2025 2025-12-31 | $225.6M | +78.1% | $71.9M | +143.4% | 31.9% |
Q3 2025 2025-09-30 | $150.9M | +31.0% | $-6.7M | +2.1% | -4.4% |
Q2 2025 2025-06-30 | $101.0M | -22.4% | $-9.4M | +44.9% | -9.3% |
Q1 2025 2025-03-31 | $86.7M | -21.2% | $-18.8M | -797.3% | -21.7% |
Q4 2024 2024-12-31 | $126.7M | — | $29.6M | — | 23.3% |
Q3 2024 2024-09-30 | $115.2M | +6.1% | $-6.8M | -315.1% | -5.9% |
Q2 2024 2024-06-30 | $130.2M | +11.0% | $-17.0M | -826.2% | -13.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ORGO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$765.4K
Insider selling
$2.7M
Net activity
−$1.9M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-03-09 | Arthur S Leibowitz Director | Purchase | 5,000 | $2.68 | $13.4K | |
| 2026-03-09 | Michael Joseph Driscoll Director | Purchase | 10,000 | $2.67 | $26.7K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ORGO
Institutional value
$46.6M
Total shares held
22.2M
Distinct holders
63
-82 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4.9M | $11.6M | +138.7K (+2.9%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $6.9M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 2.9M | $6.9M | +160.0K (+5.9%) | Added |
| 4 | Assenagon Asset Management S.A. | 2.0M | $4.7M | -3.6M (-64.4%) | Trimmed |
| 5 | DEUTSCHE BANK AG\ | 1.7M | $4.0M | -1.6M (-48.3%) | Trimmed |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4M | $3.4M | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 498.5K | $1.2M | — | New |
| 8 | LOS ANGELES CAPITAL MANAGEMENT LLC | 491.8K | $1.2M | +364.0K (+284.6%) | Added |
| 9 | Wealth Dimensions Group, Ltd. | 408.0K | $966.9K | +0 (+0.0%) | No change |
| 10 | HighMark Wealth Management LLC | 303.0K | $718.2K | +0 (+0.0%) | No change |
| 11 | Bank of New York Mellon Corp | 293.7K | $696.0K | -9.0K (-3.0%) | Trimmed |
| 12 | UBS Group AG | 207.5K | $491.8K | +74.9K (+56.5%) | Added |
| 13 | Voya Investment Management LLC | 190.5K | $451.5K | +102.7K (+117.0%) | Added |
| 14 | Nuveen, LLC | 188.7K | $447.3K | -85.2K (-31.1%) | Trimmed |
| 15 | Invesco Ltd. | 162.7K | $385.7K | -12.5K (-7.1%) | Trimmed |
| 16 | PRUDENTIAL FINANCIAL INC | 145.9K | $345.8K | -24.3K (-14.3%) | Trimmed |
| 17 | JANE STREET GROUP, LLC | 129.3K | $306.5K | -752.4K (-85.3%) | Trimmed |
| 18 | RHUMBLINE ADVISERS | 80.0K | $189.6K | -7.9K (-8.9%) | Trimmed |
| 19 | Palumbo Wealth Management LLC | 57.8K | $137.1K | +19.8K (+52.0%) | Added |
| 20 | Farther Finance Advisors, LLC | 57.4K | $132.6K | +48.2K (+520.2%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ORGO's latest filing finishes processing.